Published TCIMAIL newest issue No.201
Maximum quantity allowed is 999
CAS RN: 755037-03-7 | Product Number: R0142
Regorafenib
Purity: >98.0%(HPLC)
| Size | Unit Price | Belgium | Japan* | Quantity |
Shipping Information
|
|---|---|---|---|---|---|
| 25MG |
68,00 €
|
1 | 30 |
|
|
| 100MG |
186,00 €
|
Contact Us | 14 |
|
* Stock available in Belgium: Shipment on the same day
* Stock available in Japan: Please check the Shipping Simulation for estimated shipments. (excludes regulated items and dry ice shipments)
| Product Number | R0142 |
Purity / Analysis Method
|
>98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__2__1H__1__5ClF__4N__4O__3 = 482.82 |
| Physical State (20 deg.C) | Solid |
Storage Temperature
|
Frozen (<0°C) |
| Condition to Avoid | Heat Sensitive |
Packaging and Container
|
25MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 755037-03-7 |
| Reaxys Registry Number | 14359949 |
| PubChem Substance ID | 354334233 |
| MDL Number | MFCD16038047 |
| Appearance | White to Light yellow to Light orange powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Elemental analysis(Nitrogen) | 11.00 to 12.20 % |
| Melting Point | 208 °C |
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H302 : Harmful if swallowed. H361 : Suspected of damaging fertility or the unborn child. H373 : May cause damage to organs through prolonged or repeated exposure. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. |
| HS Number | 2933399999 |

References
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- Regorafenib for cancer (a review)
- Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
- A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry
- Determination of regorafenib (BAY 73-4506) and its major human metabolites BAY 75-7495 (M-2) and BAY 81-8752 (M-5) in human plasma by stable-isotope dilution liquid chromatography-tandem mass spectrometry
Documents
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.